Nigel Fleeman

Summary

Affiliation: University of Liverpool
Country: UK

Publications

  1. ncbi Providing patients with information on pharmacogenetic testing
    Nigel Fleeman
    Liverpool Reviews and Implementation Group, University of Liverpool
    Nurs Stand 23:46-8. 2009
  2. ncbi Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    N Fleeman
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Health Technol Assess 14:47-53. 2010
  3. ncbi Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses
    N Fleeman
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Pharmacogenomics J 11:1-14. 2011
  4. ncbi Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal
    Adrian Bagust
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool L69 3GB, UK
    Pharmacoeconomics 28:439-48. 2010

Detail Information

Publications4

  1. ncbi Providing patients with information on pharmacogenetic testing
    Nigel Fleeman
    Liverpool Reviews and Implementation Group, University of Liverpool
    Nurs Stand 23:46-8. 2009
    ..This article outlines the key issues to be considered before recommending the use of pharmacogenetic tests, which may predict a patient's response to a particular drug...
  2. ncbi Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
    N Fleeman
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Health Technol Assess 14:47-53. 2010
    ....
  3. ncbi Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses
    N Fleeman
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool, UK
    Pharmacogenomics J 11:1-14. 2011
    ..Further research is required to improve the evidence base and to generate data on clinical validity and clinical utility...
  4. ncbi Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal
    Adrian Bagust
    Liverpool Reviews and Implementation Group, University of Liverpool, Liverpool L69 3GB, UK
    Pharmacoeconomics 28:439-48. 2010
    ..This was the first appraisal to consider the end-of-life medicines criteria introduced by NICE in January 2009...